Purpose: To develop an optimised press-coated tablets of losartan potassium using an admixture of a hydrophilic polymer, hydroxypropylmethylcellulose (HPMC) and microcrystalline cellulose (MCC) in order to achieve a predetermined lag time for chronotherapy. Methods: The press-coated tablets (PCT) containing losartan potassium in the inner core were prepared by compression-coating with HPMC 100KM alone and admixed with MCC as the outer layer in different ratios. The effect of the outer layer on the lag time of drug release was investigated. The parameters determined were tablet tensile strength, friability, drug content and in vitro dissolution. The optimised formulation was further characterized with Fourier-transform infrared spectroscopy ...
Losartan potassium is a well known orally active non-peptide angiotensin II receptor antagonist. Los...
The purpose of this study is to formulate and evaluate bilayer anti-hypertensive and anti-diabetic t...
Osmotically controlled oral drug delivery systems utilize osmotic pressure as energy source for the ...
Purpose: To develop an optimised press-coated tablets of losartan potassium using an admixture of a ...
Purpose: To develop an optimised press-coated tablets of losartan potassium using an admixture of a ...
The objective of the present study was to develop hydrophilic polymer and hydrophobic polymer based ...
Sustained release matrix tablets of 100 mg losartan potassium HCl were fabricated with two release r...
The present study was aimed towards the development of controlled release formulations of Losartan P...
In the present study, an effort was made to develop the pulsatile drug delivery of Losartan potassiu...
Objective: The objective of the present investigation was to the development of floating pulsatile d...
The aim of the present study was to develop a controlled porosity osmotic tablet of Losartan potassi...
Losartan potassium (LP) is an angiotensin receptor blocker used to treat hypertension. At higher pH,...
Angiotensin-II receptor blocker losartan, approved by the FDA in 1995, is used to treat hypertension...
Osmotically controlled oral drug delivery systems utilize osmotic pressure as energy source for the ...
The objective of the present study is optimization of losartan floating tablet formulation by 23 fac...
Losartan potassium is a well known orally active non-peptide angiotensin II receptor antagonist. Los...
The purpose of this study is to formulate and evaluate bilayer anti-hypertensive and anti-diabetic t...
Osmotically controlled oral drug delivery systems utilize osmotic pressure as energy source for the ...
Purpose: To develop an optimised press-coated tablets of losartan potassium using an admixture of a ...
Purpose: To develop an optimised press-coated tablets of losartan potassium using an admixture of a ...
The objective of the present study was to develop hydrophilic polymer and hydrophobic polymer based ...
Sustained release matrix tablets of 100 mg losartan potassium HCl were fabricated with two release r...
The present study was aimed towards the development of controlled release formulations of Losartan P...
In the present study, an effort was made to develop the pulsatile drug delivery of Losartan potassiu...
Objective: The objective of the present investigation was to the development of floating pulsatile d...
The aim of the present study was to develop a controlled porosity osmotic tablet of Losartan potassi...
Losartan potassium (LP) is an angiotensin receptor blocker used to treat hypertension. At higher pH,...
Angiotensin-II receptor blocker losartan, approved by the FDA in 1995, is used to treat hypertension...
Osmotically controlled oral drug delivery systems utilize osmotic pressure as energy source for the ...
The objective of the present study is optimization of losartan floating tablet formulation by 23 fac...
Losartan potassium is a well known orally active non-peptide angiotensin II receptor antagonist. Los...
The purpose of this study is to formulate and evaluate bilayer anti-hypertensive and anti-diabetic t...
Osmotically controlled oral drug delivery systems utilize osmotic pressure as energy source for the ...